US Dollar vs MXN

Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

Regístrate

MRK Merck and Co Inc

130.89

3.89 (3.06%)

25 Abr 2024 - Cerrado

Retrasado por 15 minutos

A very strong day for Merck & Company Inc stock price on Friday

The Merck & Company Inc stock price gained 8.37% on the last trading day (Friday, 1st Oct 2021), ris... View Full Article on StockInvest.us

Merck (NYSE:MRK)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Haga Click aquí para más Gráficas Merck.

Merck (NYSE:MRK)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024

Haga Click aquí para más Gráficas Merck.

Noticias sobre Merck and Co Inc MRK

U.S. Stocks Climb Well Off Worst Levels But Close Mostly Lower
Jueves 25 de Abril 2024 (7 horas hace) • IH Market News

Futures Pointing To Sharply Lower Open On Wall Street
Jueves 25 de Abril 2024 (15 horas hace) • IH Market News

Southwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on Earnings
Jueves 25 de Abril 2024 (16 horas hace) • IH Market News

Merck Announces First-Quarter 2024 Financial Results
Jueves 25 de Abril 2024 (18 horas hace) • Business Wire

Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-conta
Viernes 19 de Abril 2024 (7 días hace) • PR Newswire (Canada)

Delta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More News
Miércoles 10 de Abril 2024 (2 semanas hace) • IH Market News

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Jueves 4 de Abril 2024 (3 semanas hace) • Business Wire

REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Miércoles 3 de Abril 2024 (3 semanas hace) • Business Wire

Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
Lunes 1 de Abril 2024 (4 semanas hace) • Business Wire

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
Jueves 28 de Marzo 2024 (4 semanas hace) • Business Wire

GameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More News
Miércoles 27 de Marzo 2024 (4 semanas hace) • IH Market News

FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
Martes 26 de Marzo 2024 (1 mes hace) • Business Wire

Más de Merck and Co Inc Artículos de Noticias

Bank of America

Invesco QQQ Trust Series 1

Health Care Select Sector

BNP Paribas (QX)

Deutsche Telekom (QX)

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones